Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P41586
UPID:
PACR_HUMAN
Alternative names:
-
Alternative UPACC:
P41586; A8K1Y1; B7ZLA7; B8ZZK3; Q17S10
Background:
The Pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1R) is a key receptor for PACAP-27 and PACAP-38, playing a pivotal role in various physiological processes. It activates adenylyl cyclase through G proteins, influencing the release of hormones such as adrenocorticotropin and growth hormone, and is involved in spermatogenesis, sperm motility, smooth muscle relaxation, and gastrointestinal secretion.
Therapeutic significance:
Understanding the role of Pituitary adenylate cyclase-activating polypeptide type I receptor could open doors to potential therapeutic strategies.